Posted April 30, 2013
Nora K. Frisch, MD
Melanoma is an increasingly common diagnosis, with more than 75,000 new cases each year.1 Unlike many other cancers, melanoma does not respond to traditional chemotherapy or radiation. Because treatment options are limited, there is a significant need for pharmaceutical research and development. Recent advances in molecular diagnostics have led to the development of targeted therapies for certain types of melanomas.
Approximately 65% of melanomas harbor somatic mutations of BRAF, a gene that is part of the mitogen-activated protein kinase (MAPK) pathway.2,3 Commonly, BRAF mutations are associated with thinner primary lesions and tend to develop in skin without chronic sun damage.4 BRAF mutations lead to increased tyrosine kinase activity and cell proliferation.3,5 In 80% of patients harboring a mutation, the mutation is a single-point substitution where a glutamic acid is replaced by a valine at residue 600 (V600E). Patients with a proven V600E BRAF mutation are eligible for treatment with selective BRAF inhibitors, such as vemurafenib and dabrafenib. These patients have an overall response rate of greater than 50% and show improvement in both progression-free survival as well as overall survival.3
When melanoma develops in chronically sun-exposed skin or exhibits a nodular growth pattern, it is more likely to have a mutation in NRAS.3,5,6 NRAS is also part of the MAP Kinase pathway and is located upstream from BRAF. Mutations in NRAS result in constitutive activation of BRAF, which then causes uncontrolled cell proliferation. In general, BRAF and NRAS mutations are mutually exclusive. Although there are no targeted therapies for tumors with NRAS mutations, it is important to document NRAS mutations since these tumors can respond negatively when treated with selective BRAF inhibitors.7 It has been hypothesized that this phenomenon is due to enhanced activation of downstream proteins in the MAPK pathway when subjected to BRAF inhibition.9
Another type of mutation found in melanomas involves the KIT gene. Typically, KIT mutations are found in acral and mucosal melanomas, as well as melanomas of chronically sun-exposed skin.8,10 This mutation is mutually exclusive with the BRAF/NRAS mutations and involves activation of a tyrosine kinase. The KIT mutation is an ideal target for molecular testing because targeted therapeutic agents, tyrosine kinase inhibitors (TKIs), have already been developed. Moreover, treatment with TKIs has led to greatly improved short-term survival for patients with other KIT-mutated tumors, such as gastrointestinal stromal tumors.11 To date, early studies in KIT-mutated melanoma show promising results.8,10
In conclusion, several molecular aberrations have been identified within melanoma. Before ordering molecular testing, clinicians should consider the type of melanoma (eg, cutaneous versus acral) and whether there are any metastases. Patients with cutaneous melanoma should first be tested for BRAF (+/- NRAS), and then tested for KIT if the first results are negative. On the other hand, patients with acral or mucosal melanomas should be tested for BRAF (+/- NRAS) and KIT mutations simultaneously. If the patient has metastatic disease, the preferred specimen is the most recent metastasis since this tissue is felt to provide the most accurate representation of current tumor biology.8 Overall, it is important for clinicians to understand the basics principles of molecular diagnostics in melanoma in order to facilitate the most current and efficacious treatment for their patients.
- Melanoma skin cancer. American Cancer Society website. http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics. Updated January 17, 2013. Accessed April 24, 2013.
- Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med. 2010;8:38. doi: 10.1186/1479-5876-8-38.
- Dadras SS. Molecular diagnostics in melanoma: current status and perspectives. Arch Pathol Lab Med. 2011;135(7): 860–869. doi: 10.1043/2009-0623-RAR1.1.
- Lee JH, Choi JW, Kim YS. “Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.” Br J Dermatol. 2011; 164(4):776–784. doi: 10.1111/j.1365-2133.2010.10185.x.
- Held L, Eigentler TK, Meier F, et al. Oncogenetics of melanoma: basis for molecular diagnostics and therapy. J Dtsch Dermatol Ges. 2011;9(7):510–516. doi: 10.1111/j.1610-0387.2011.07603.x.
- Wilson MA, Nathanson KL. Molecular testing in melanoma. Cancer J. 2012;18(2):117–23. doi: 10.1097/PPO.0b013e31824f11bf.
- Woodman SE, Lazar AJ, Aldape KD, Davies MA. New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res. 2012;18(5):1195–1200. doi: 10.1158/1078-0432.CCR-11-2317.
- Postow MA, Carvajal RD. Therapeutic implications of KIT in melanoma. Cancer J. 2012; 18(2):137–141. doi: 10.1097/PPO.0b013e31824b2404.
- Callahan MK, Rampal R, Harding JJ, et al. “Progression of RAS-mutant leukemia during RAF inhibitor treatment.” N Engl J Med. 2012;367(24):2316–2321. doi: 10.1056/NEJMoa1208958.
- Woodman S, Davies M. “Targeting KIT in Melanoma: a paradigm of molecular medicine and targeted therapeutics.” Biochem Pharmacol. 2010;80(5):568–574. doi: 10.1016/j.bcp.2010.04.032.
- Gastrointestinal stromal tumor. American Cancer Society website. http://www.cancer.org/cancer/gastrointestinalstromaltumorgist/detailedguide/gastrointestinal-stromal-tumor-survival-rates. Updated February 26, 2013. Accessed April 24, 2013.
Download this article in Microsoft Word format.
Download this article in PDF format.
NewsPath® Editor: Kyle L. Eskue, MD, FCAP
This newsletter is produced in cooperation with the College of American
Pathologists Member and Public Communications Committee and the NewsPath Editorial Board
and may be reproduced in whole or in part as a service to the medical community.
Copyright © 2013 by
the College of American Pathologists.
Please e-mail any comments to firstname.lastname@example.org.